Actively Recruiting
Long-Term Monitoring of Patients After Miltenyi CAR T Cell Treatments to Assess Safety and Disease Progression
Led by Miltenyi Biomedicine GmbH · Updated on 2026-10-09
40
Participants Needed
7
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This trial focuses on patients who previously received Miltenyi CAR T cell therapies. It aims to evaluate the long-term safety and effectiveness of these treatments by monitoring any late side effects and disease progression. The study includes patients treated for various conditions including melanoma, B-cell non-Hodgkin lymphoma, and pediatric acute lymphatic leukemia. Participants will be assessed over a period of up to 14 years following their initial CAR T cell therapy. The study monitors adverse reactions, serious events, disease relapse or progression, and survival. It also tracks relevant lab markers such as lymphocyte counts and detects presence of the CAR T cell transgene and replication-competent lentivirus. During the trial, participants will undergo periodic evaluations including clinical assessments and laboratory tests. Pediatric patients will have developmental milestones tracked using Tanner staging and menstruation status. The main outcomes measured are adverse events over the entire study duration. This long-term follow-up helps researchers better understand the lasting effects and risks of these gene therapies.
CONDITIONS
Brief Title
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
Research Team
C
Clinical Trial Manager
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here